Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 152

Related Citations for PubMed (Select 20332000)

1.

Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.

El-Alfy AT, Ivey K, Robinson K, Ahmed S, Radwan M, Slade D, Khan I, ElSohly M, Ross S.

Pharmacol Biochem Behav. 2010 Jun;95(4):434-42. doi: 10.1016/j.pbb.2010.03.004. Epub 2010 Mar 21.

2.

Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.

DeLong GT, Wolf CE, Poklis A, Lichtman AH.

Drug Alcohol Depend. 2010 Nov 1;112(1-2):126-33. doi: 10.1016/j.drugalcdep.2010.05.019.

3.

Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor.

Fischedick J, Van Der Kooy F, Verpoorte R.

Chem Pharm Bull (Tokyo). 2010 Feb;58(2):201-7.

4.

Inhibition of the cataleptic effect of tetrahydrocannabinol by other constituents of Cannabis sativa L.

Formukong EA, Evans AT, Evans FJ.

J Pharm Pharmacol. 1988 Feb;40(2):132-4.

PMID:
2897447
5.

Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception.

Booker L, Naidu PS, Razdan RK, Mahadevan A, Lichtman AH.

Drug Alcohol Depend. 2009 Nov 1;105(1-2):42-7. doi: 10.1016/j.drugalcdep.2009.06.009. Epub 2009 Aug 12.

6.

Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol.

Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR, Wiley JL.

Drug Alcohol Depend. 2008 Apr 1;94(1-3):191-8. doi: 10.1016/j.drugalcdep.2007.11.017.

7.

[Quantitative analysis and pharmaco-toxicity of cannabinoids in commercially available cannabis seeds].

Matsunaga T, Watanabe K, Yoshimura H, Yamamoto I.

Yakugaku Zasshi. 1998 Sep;118(9):408-14. Japanese.

PMID:
9779001
8.

Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors.

Zanelati TV, Biojone C, Moreira FA, Guimarães FS, Joca SR.

Br J Pharmacol. 2010 Jan;159(1):122-8. doi: 10.1111/j.1476-5381.2009.00521.x. Epub 2009 Dec 4.

9.

Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects.

Roser P, Gallinat J, Weinberg G, Juckel G, Gorynia I, Stadelmann AM.

Eur Arch Psychiatry Clin Neurosci. 2009 Aug;259(5):284-92. doi: 10.1007/s00406-009-0868-5. Epub 2009 Feb 17.

PMID:
19224107
10.

Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.

De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, Stott CG, Di Marzo V.

Br J Pharmacol. 2011 Aug;163(7):1479-94. doi: 10.1111/j.1476-5381.2010.01166.x.

11.

Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism.

Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K, Egawa T, Kitamura Y, Uchida N, Nishimura R, Egashira N, Iwasaki K, Fujiwara M.

Brain Res. 2008 Jan 10;1188:157-64. Epub 2007 Oct 12.

PMID:
18021759
12.

A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.

Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T.

Int J Neuropsychopharmacol. 2010 Aug;13(7):861-76. doi: 10.1017/S1461145709990605. Epub 2009 Sep 29.

PMID:
19785914
13.

Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures.

Moldzio R, Pacher T, Krewenka C, Kranner B, Novak J, Duvigneau JC, Rausch WD.

Phytomedicine. 2012 Jun 15;19(8-9):819-24. doi: 10.1016/j.phymed.2012.04.002. Epub 2012 May 7.

PMID:
22571976
14.

Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile.

Swift W, Wong A, Li KM, Arnold JC, McGregor IS.

PLoS One. 2013 Jul 24;8(7):e70052. doi: 10.1371/journal.pone.0070052. Print 2013.

15.

Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THC.

Lile JA, Kelly TH, Hays LR.

Drug Alcohol Depend. 2011 Jul 1;116(1-3):86-92. doi: 10.1016/j.drugalcdep.2010.11.019. Epub 2011 Jan 11.

16.

Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?

Lee D, Karschner EL, Milman G, Barnes AJ, Goodwin RS, Huestis MA.

Drug Alcohol Depend. 2013 Jun 1;130(1-3):68-76. doi: 10.1016/j.drugalcdep.2012.10.011. Epub 2012 Nov 10.

17.

Evidence for the involvement of the serotonergic 5-HT2A/C and 5-HT3 receptors in the antidepressant-like effect caused by oral administration of bis selenide in mice.

Jesse CR, Wilhelm EA, Bortolatto CF, Nogueira CW.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Mar 17;34(2):294-302. doi: 10.1016/j.pnpbp.2009.11.023. Epub 2009 Dec 2.

PMID:
19961893
19.

Analgesic and antiinflammatory activity of constituents of Cannabis sativa L.

Formukong EA, Evans AT, Evans FJ.

Inflammation. 1988 Aug;12(4):361-71.

PMID:
3169967
20.

Delta9-THC as a discriminative cue in pigeons: effects of delta8-THC, CBD, and CBN.

Järbe TU, Henriksson BG, Ohlin GC.

Arch Int Pharmacodyn Ther. 1977 Jul;228(1):68-72.

PMID:
921403
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk